Keywords
Hepatitis C
Kidney Dialysis
Seroepidemiological Studies
Comorbidity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To characterize the clinical-epidemiological profile and seroprevalence of patients treated at a hemodialysis reference center in Belém-PA, in January 2022. Methods: This is a cross-sectional prevalence study, with 116 patients of both sexes, of 18 to 81 years old. Data collection by surveying medical records data, the clinical-epidemiological profile and seroprevalence for viral hepatitis B and C were investigated. Results: Of the 116 patients, 60.34% were men and 32.76% belonged to the age group of 48 - 62 years old, 44.82% had hemodialysis time > 60 months. The main etiologies causing renal failure: hypertensive nephrosclerosis (23.27%) and diabetic nephropathy (18.10%). Seroprevalence: reactive anti-HBs (75.00%), non-reactive total anti-HBc (83.03%), non-reactive HBsAg (100%) and non-reactive anti-HCV (95.49%). Excluding those vaccinated, there was a significant association between natural immunization with the Hepatitis B virus and hemodialysis time greater than 60 months. Conclusion: A higher prevalence of reactive anti-HBs, non-reactive total anti-HBc and non-reactive HBsAg was observed. As for Hepatitis C, there is a higher frequency of nonreactive anti-HCV. Furthermore, it will be necessary to progress the study with molecular biology tests to better assess the prevalence of Hepatitis B and C infection.
References
ADANE T e GETAWA S. The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis. PloS one. 2021; 16(6): e0251570.
ANEES M, et al. Factors Associated with Seroconversion of Hepatitis C Virus in End Stage Renal Disease Patients. Journal of the College of Physicians and Surgeons—Pakistan: JCPSP. 2021; 31(9): 1040–1045.
AWAD AM, et al. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Vaccine. 2021; 39(25): 3346–3352.
BRASIL. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada, RDC n° 11, de 13 de março de 2014. Dispõe sobre os requisitos de boas práticas de funcionamento para os Serviços de Diálise e dá outras providências. Diário Oficial da União; Poder Executivo, Brasília, DF. 2014; 13.
BURDICK RA, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney international. 2003; 63(6): 2222–2229.
CAI G, et al. Factors Correlating to the Development of Hepatitis C Virus Infection in Hemodialysis Patients-Findings Mainly from Asiatic Populations: A Systematic Review and Meta-Analysis. International journal of environmental research and public health. 2019; 16(8): 1453.
CONSTANCIO NS, et al. Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach. Jornal brasileiro de nefrologia: órgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2019; 41(4): 539–549.
CORDEIRO VM, et al. Decline in hepatitis B and C prevalence among hemodialysis patients in Tocantins, Northern Brazil. Revista do Instituto de Medicina Tropical de São Paulo. 2018; 60: e36.
DE ARRUDA LD e FLORES AMN. Educação em saúde acerca das hepatites virais com pacientes renais crônicos em hemodiálise. Brazilian Journal of Development. 2022; 8(2): 11883–11897.
FABRIZI F e CERUTTI, R., & MESSA, P. Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis. Pathogens (Basel, Switzerland). 2021; 10(9): 1149.
FENG Y, et al. Predicting related factors of immunological response to hepatitis B vaccine in hemodialysis patients based on integration of decision tree classification and logistic regression. Human vaccines & immunotherapeutics. 2021; 17(9): 3214–3220.
FISSELL RB, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney international. 2004; 65(6): 2335–2342.
HEIKENS E, et al. Hepatitis C virus transmission in a Dutch haemodialysis unit: detailed outbreak investigation using NS5A gene sequencing. The Journal of hospital infection. 2019; 101(3): 333–338.
HSU PY, et al. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. Journal of gastroenterology and hepatology. 2021; 36(8): 2261–2269.
JEELE M, et al. Prevalence and Risk Factors Associated with Hepatitis B and Hepatitis C Infections among Patients Undergoing Hemodialysis: A Single-Centre Study in Somalia. International journal of nephrology. 2021; 1555775.
MACIEL RO, et al. de. Nefropatia diabética – insuficiência e fatores de risco associados. Brazilian Journal of Health Review. 2019; 2(4): 3808-3823.
MOURA-NETO JA, et al. Brazilian registry for the elimination of hepatitis C in dialysis units: a call to action for Nephrology. Jornal brasileiro de nefrologia: órgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia. 2022; 44(1): 109–111.
MSOMI N, et al. Alta taxa de infecção oculta pelo vírus da hepatite B em unidades de hemodiálise de KwaZulu-Natal, África do Sul. J Med Virol. 2019; 91: 1797-1803.
NIQUINI RP, et al. Persistently high hepatitis C rates in haemodialysis patients in Brazil [a systematic review and meta-analysis]. Scientific reports. 2022; 12(1): 330.
PERESON MJ, et al. Seroprevalence of hepatitis B, hepatitis C and HIV infection among patients undergoing haemodialysis in Buenos Aires, Argentina. Journal of medical microbiology. 2021; 70(1): 1278.
SILVA TK. Diabetes mellitus e hipertensão arterial em pacientes com insuficiência renal crônica em diálise: Revisão integrativa. Research, Society and Development. 2021; 10(6): e53410616121.
SOUSA LFO, et al. Mortalidade por hepatites no Brasil e regiões, 2001–2020: tendência temporal e análise espacial. Revista Brasileira de Epidemiologia. 2023; 26: e230029.
THOMÉ SF, et al. Inquérito Brasileiro de Diálise Crônica 2017. Braz. J. Nephrol. 2019; 41(2): 208-214.
TURNER JM e PEIXOTO AJ. Blood pressure targets for hemodialysis patients. Kidney international. 2017; 92(4): 816-823.
UDOMKARNJANANUN S, et al. Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis. Journal of nephrology. 2020; 33(2): 343–354.
WINSTON A, et al. Viral hepatitis in patients on hemodialysis. Seminars in dialysis, 2020; 33(3): 254–262.
WORD HEALTH ORGANIZATION (WHO). Technical considerations and case definitions to improve surveillance for viral hepatitis: technical report. 2016; 72.
WU YT, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2021; 42(9): 1566–1572.
YAO T, et al. Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China. Vaccine. 2021: 39(18): 2537–2544.